<span item_type="fundamental" item_id="ace687fdefbe06622f5b83b76df8f86d" counter_id="ST/US/KURA" env="prod"></span><span item_type="announcement" item_id="647651736055778049" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 18.27 M, missing the estimate of USD 25.92 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.83, missing the estimate of USD -0.8244.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -78.82 M.</p><p></p><h3>Financial Performance Summary</h3><h4>Revenue</h4><ul><li><strong>Product revenue, net</strong>: Kura Oncology, Inc. recognized $5.8 million for the three months ended March 31, 2026, compared to $0 for the same period in 2025, an increase of $5.766 million due to the commercial launch of KOMZIFTI in November 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Collaboration revenue</strong>: Totaled $12.5 million for the three months ended March 31, 2026, a decrease of - $1.609 million from $14.1 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Total revenue</strong>: Was $18.265 million for the three months ended March 31, 2026, up from $14.108 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li><strong>Cost of product sales</strong>: Amounted to $0.262 million for the three months ended March 31, 2026, with no cost of product sales in the prior year period, reflecting the commercialization of KOMZIFTI.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Research and development expenses</strong>: Increased by $9.290 million to $65.263 million for the three months ended March 31, 2026, from $55.973 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span><ul><li><strong>Ziftomenib-related costs</strong>: Increased by $6.933 million to $36.880 million for the three months ended March 31, 2026, primarily due to increased costs for ziftomenib combination trials, including registration-directed frontline clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Darlifarnib-related costs</strong>: Increased by $1.332 million to $6.567 million for the three months ended March 31, 2026, primarily due to increased costs related to its Phase 1 clinical trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Discovery stage program-related costs</strong>: Decreased by - $0.689 million to $1.400 million for the three months ended March 31, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Personnel costs and other expenses (R&amp;D)</strong>: Increased by $1.827 million to $17.201 million for the three months ended March 31, 2026, primarily due to increased headcount to support ongoing clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li></ul></li><li><strong>Selling, general and administrative expenses</strong>: Increased by $8.720 million to $31.555 million for the three months ended March 31, 2026, from $22.835 million in the prior year period, primarily due to increases in personnel costs, sales and marketing expenses, and non-cash share-based compensation expense.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li></ul><h4>Other Income (Expense)</h4><ul><li><strong>Other income, net</strong>: Decreased by - $2.007 million to $5.490 million for the three months ended March 31, 2026, primarily due to a decrease in interest income.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Kura Oncology, Inc. reported a net loss of - $73.333 million for the three months ended March 31, 2026, compared to a net loss of - $57.429 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li></ul><h4>Cash Flow</h4><ul><li><strong>Net cash used in operating activities</strong>: Increased by - $13.927 million to - $85.854 million for the three months ended March 31, 2026, compared to - $71.927 million for the same period in 2025, primarily due to increases in net loss and changes in operating assets and liabilities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Net cash used in investing activities</strong>: Decreased by $77.178 million to - $24.231 million for the three months ended March 31, 2026, compared to - $101.409 million for the same period in 2025, primarily due to decreases in purchases of short-term investments and property and equipment, partially offset by a decrease in maturities of short-term investments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li><strong>Net cash provided by financing activities</strong>: Decreased by - $0.074 million to $0.069 million for the three months ended March 31, 2026, compared to $0.143 million for the same period in 2025, relating to proceeds from stock issuance under equity plans.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li></ul><h4>Liquidity and Capital Resources</h4><ul><li>As of March 31, 2026, Kura Oncology, Inc. had cash, cash equivalents, and short-term investments totaling $580.8 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li>The company believes its current cash, cash equivalents, and short-term investments will fund its operating plan into the fourth quarter of 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li><li>Combined with an anticipated $180.0 million from the Kyowa License Agreement, Kura Oncology, Inc. expects to have sufficient capital to advance its ziftomenib AML program through the first topline results from KOMET-017, anticipated in 2028.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></li></ul><h3>Strategic Outlook and Development</h3><h4>KOMZIFTI (ziftomenib)</h4><p>Kura Oncology, Inc. initiated commercial sales of KOMZIFTI in the United States on November 21, 2025, after FDA approval on November 13, 2025, for relapsed or refractory NPM1-mutated AML.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span> The company is advancing the global clinical development of ziftomenib, including combinations with standards of care for AML and in frontline and relapsed or refractory disease settings.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span> Topline results for the MRD-negative CR accelerated endpoint from the registrational KOMET-017-IC trial are anticipated in 2028, and preliminary data for ziftomenib in combination with gilteritinib are expected in the second half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></p><h4>Next-Generation Menin Inhibitors</h4><p>Kura Oncology, Inc. nominated KO-7246 as its first next-generation menin inhibitor, planning to advance it into IND-enabling studies for diabetes and cardiometabolic diseases in 2026, potentially with external investment or collaboration.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span> Preclinical data on menin inhibitors in diabetes are anticipated in 2026, and the company also expects to advance preclinical development of an additional next-generation menin inhibitor for combination therapy in solid tumors in 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></p><h4>Darlifarnib</h4><p>The FIT-001 trial is evaluating darlifarnib in combination with cabozantinib in RCC, with Phase 1b dose expansion cohorts initiated in February 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span> Updated Phase 1a dose-escalation data for darlifarnib and cabozantinib are expected in the second half of 2026, and preliminary clinical data from the dose escalation portion of darlifarnib with adagrasib were accepted for presentation on May 30, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span> Kura Oncology, Inc. plans to explore opportunities for additional indications and combination partners for darlifarnib in 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1422143/000119312526219481/kura-20260331.htm"></span></p>

Kura Oncology | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 18.27 M